dianicline

an alpha4beta2 nicotinic receptor agonist; may be useful as an aid in quitting smoking; structure in first source

Also Known As:

5a,6,9,10-tetrahydro-7H,11H-8,10a-methanopyrido(2',3'-5,6)pyrano(2,3-d)azepine; SSR 591813; SSR-591813; SSR591813

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Tobacco Use Disorder (Nicotine Dependence) 07/01/2003 - "The present results confirm important role for alpha4beta2 nAChRs in mediating nicotine dependence and suggest that SSR591813, a partial agonist at this particular nAChR subtype, may have therapeutic potential in the clinical management of smoking cessation." 07/01/2003 - "SSR591813 shows activity in animal models of nicotine dependence at doses devoid of unwanted side effects typically observed with nicotine (hypothermia and cardiovascular effects). " 05/01/2010 - "Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence."
2.	Substance Withdrawal Syndrome (Withdrawal Symptoms) 01/01/2011 - "Nicotine withdrawal symptoms measured by the Hughes and Hatsukami Minnesota Withdrawal Scale were lower for dianicline compared with placebo in the first 3 weeks of treatment during which time quit rates were also higher in the dianicline-treated group. "
3.	Hypothermia 07/01/2003 - "SSR591813 shows activity in animal models of nicotine dependence at doses devoid of unwanted side effects typically observed with nicotine (hypothermia and cardiovascular effects). "

1.	Nicotine
2.	Varenicline (Chantix)
3.	nicotinic receptor alpha4beta2
4.	cytisine